KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bausch Health Companies (BHC) Cash & Equivalents: 2009-2024

Historic Cash & Equivalents for Bausch Health Companies (BHC) over the last 16 years, with Dec 2024 value amounting to $1.2 billion.

  • Bausch Health Companies' Cash & Equivalents rose 81.92% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year increase of 81.92%. This contributed to the annual value of $1.2 billion for FY2024, which is 24.71% up from last year.
  • According to the latest figures from FY2024, Bausch Health Companies' Cash & Equivalents is $1.2 billion, which was up 24.71% from $947.0 million recorded in FY2023.
  • Over the past 5 years, Bausch Health Companies' Cash & Equivalents peaked at $1.2 billion during FY2024, and registered a low of $564.0 million during FY2022.
  • Over the past 3 years, Bausch Health Companies' median Cash & Equivalents value was $947.0 million (recorded in 2023), while the average stood at $897.3 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first tumbled by 81.34% in 2020, then skyrocketed by 67.91% in 2023.
  • Bausch Health Companies' Cash & Equivalents (Yearly) stood at $605.0 million in 2020, then declined by 3.80% to $582.0 million in 2021, then fell by 3.09% to $564.0 million in 2022, then surged by 67.91% to $947.0 million in 2023, then grew by 24.71% to $1.2 billion in 2024.